IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma

British Journal of Haematology

Volumn 141, Issue 2, 2008, Pages 244-248

  Fox, C P ^a,b   McMillan, A K ^a   Bishton, M J ^a   Haynes, A P ^a   Russell, N H ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Autologous stem cell transplantation; Chemotherapy; Lymphoma; Salvage therapy; Stem cell mobilisation

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CD34 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CD34 SELECTION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; FEMALE; HODGKIN DISEASE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PATIENT MOBILITY; PRIORITY JOURNAL; SALVAGE THERAPY; STEM CELL MOBILIZATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG EVALUATION; EPIRUBICIN; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IFOSFAMIDE; LYMPHOMA; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 40949151130     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07068.x     Document Type: Article

References (19)

1. Bishton, M.J., Lush, R.J., Byrne, J.L., Russell, N.H., Shaw, B.E. Haynes, A.P. (2007) Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. British Journal of Haematology, 136, 752 761.
2. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I, Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. Canellos, G.P. (1999) Report of an international workshop to standardise response criteria for non-Hodgkin lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 18, 2351.
3. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.L., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology 25, 579 586.
4. Faulkner, R.D., Craddock, C., Byrne, J.L., Mahendra, P., Haynes, A.P., Prentice, H.G., Potter, M., Pagliuca, A., Ho, A., Devereux, S., McQuaker, G., Mufti, G., Yin, J.L. Russel, N.H. (2004) BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood, 103, 428 434.
5. Goldman, J.M., Schmitz, N., Niethammer, D. Gratwohl, A. (1998) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Bone Marrow Transplantation, 21, 1 7.
6. Gulati, S., Yahalom, J., Acaba, L., Reich, L., Motzer, R., Crown, J., Toia, M., Igarashi, T., Lemoli, R. Hanninen, E. (1992) Treatment of patients with relapsed and resistant NHL using total body irradiation, etoposide, and cyclophosphamide and ABMT. Journal of Clinical Oncology, 10, 936 941.
7. Hertzberg, M.S., Crombie, C., Benson, W., Taper, J., Gottlieb, D. Bradstock, K.F. (2006) Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin and Hodgkin lymphoma. Annals of Oncology, 17, 25 30.
8. Jerkeman, M., Leppä, S., Kvaløy, S. Holte, H. (2004) ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma-the Nordic Lymphoma Group experience. European Journal of Haematology, 73, 179 182.
9. Kewalramani, T., Zelenetz, A.D., Nimer, S.D., Portlock, C., Straus, D., Noy, A., O'Connor, O., Filippa, D.A., Teruya-Feldstein, J., Gencarelli, A., Oin, J., Waxman, A., Yahalom, J. Moskowitz, C.H. (2004) Rituximab and ICE as 2nd line therapy before autologous stem cell transplantation for relapsed or primary refractory DLBL. Blood, 103, 3684 3688.
10. McQuaker, I.G., Haynes, A.P., Stainer, C., Anderson, S. Russell, N.H. (1997) Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosfamide, etoposide and epirubicin compared to intermediate dose cyclophosphamide. British Journal of Haematology, 98, 228 233.
11. Moskowitz, C.H., Bertino, J.R., Glassman, J.R., Hedrick, E.E., Hunte, S., Coady-Lyons, N., Agus, D.B., Goy, A., Jurcic, J., Noy, A., O'Brien, J., Portlock, C.S., Straus, D.S., Childs, B., Frank, R., Yahalom, J., Filippa, D., Louie, D., Nimer, S.D. Zelenetz, A.D. (1999) Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-hodgkin lymphoma. Journal of Clinical Oncology, 17, 3776 3785.
12. Oliveri, A., Offidani, M., Ciniero, L., Cantori, I., Ombrosi, L., Mancini, S., Masia, M.C., Scalari, P. Leoni, P. (1995) DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Bone Marrow Transplantation, 16, 85 93.
13. Philip, T., Armitage, J.O., Spitzer, G., Chauvin, F., Jagannath, S., Cahn, J.Y., Colombat, P., Goldstone, A.H., Gorin, N.C. Flesh, M. (1987) High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate or high grade NHL. New England Journal of Medicine, 316, 1493 1498.
14. Russell, N.H. Pacey, S. (1992) Economic evaluation of peripheral blood stem cell transplantation for lymphoma. The Lancet, 340, 1290 1290.
15. Russell, N.H., McQuaker, G., Stainer, C., Byrne, J.L. Haynes, A.P. (1998) Stem cell mobilisation in lymphoproliferative diseases. Bone Marrow Transplantation, 22, 935 940.
16. Schmitz, N., Linch, D.C., Dreger, P., Goldstone, A.H., Boogaerts, M.A., Ferrant, A., Demuynck, H.M., Link, H., Zander, A. Barge, A. (1996) Randomised trial of Filgrastim-mobilised peripheral blood progenitor transplantation versus autologous bone marrow transplantation in lymphoma patients. The Lancet, 347, 353.
17. Vose, J.M., Anderson, J.R., Kessinger, A., Bierman, P.J., Coccia, P., Reed, E.C., Gordon, B. Armitage, J.O. (1993) High dose chemotherapy and ASCT for aggressive NHL. Journal of Clinical Oncology, 11, 1846 1853.
18. Watts, M.J., Ings, S.J., Leverett, D., MacMillan, A., Devereux, S., Goldstone, A.H. Linch, D.C.l. (2000) ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. British Journal of Cancer, 82, 278 82.
19. Zelenetz, A.D., Hamlin, P., Kewalramani, T., Yahalom, J., Nimer, S. Moskowitz, C.H. (2003) Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed or refractory aggressive non-Hodgkin lymphoma. Annals of Oncology, 14 (Suppl. 1 5 10.